Is Now FDA-Approved!
About Nobelpharma America, LLC
Nobelpharma America, LLC is a U.S subsidiary of a purpose-driven Japanese pharmaceutical company which is seeking to enter the U.S. market to bring drugs and medical devices to individuals whose conditions are often overlooked because of the small number of patients affected. Our “patients first” approach is to develop drugs and medical devices that target medical conditions with limited or no other treatment options, regardless of market size.
We contribute to society by developing drugs and medical devices for diseases that other pharmaceutical companies may overlook because of the small number of patients affected or for other reasons, and to deliver these drugs and devices where they are needed.
We will continue to further evolve by developing First-In-Class & Best-In-Class drugs and launch products in more regions, such as the United States and Europe.
Message from the President & CEO
Nobelpharma America, LLC is the first global subsidiary of Nobelpharma Co., Ltd. in Tokyo, Japan for the purpose of expanding our business to the United States.
- FDA approves Nobelpharma’s HYFTOR™ (sirolimus topical gel) 0.2% (April 04, 2022)
- The TSC Alliance is a resource for those affected by TSC and recently launched a support tool, the TSC Navigator (November 1, 2021)
- Nobelpharma introduced by Nature Portfolio (October 2021) *Nobelpharma products have not been approved or deemed safe and effective by the U.S. FDA and are not available for commercial sale in the U.S.
- Nobelpharma America Announces Presence at 2021 Society for Pediatric Dermatology Annual Meeting (July 6, 2021)
- Nobelpharma America Recognized by the TSC Alliance for Commitment to TSC Community (June 22, 2021)
- Tuberous Sclerosis Alliance and Nobelpharma to Celebrate Rare Disease Day with New Partnership (May 18, 2021)
- Nobelpharma America introduced by Washington Business Journal (September 1, 2020)
This website contains information about products that may not be available in the U.S. Nothing contained herein should be considered a solicitation, promotion or advertisement for any product including those under development.